10:18:54 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning IMMNOV 0.00 SEK
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-25 Årsstämma 2024
2024-02-21 Bokslutskommuniké 2023
2023-11-21 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-29 Ordinarie utdelning IMMNOV 0.00 SEK
2023-05-26 Årsstämma 2023
2023-05-23 Kvartalsrapport 2023-Q1
2023-03-16 Extra Bolagsstämma 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning IMMNOV 0.00 SEK
2022-04-07 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning IMMNOV 0.00 SEK
2021-05-06 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-09-23 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning IMMNOV 0.00 SEK
2020-05-07 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-04-29 Ordinarie utdelning IMMNOV 0.00 SEK
2019-04-26 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-04 Ordinarie utdelning IMMNOV 0.00 SEK
2018-05-03 Årsstämma 2018
2018-04-27 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-04-26 Ordinarie utdelning IMMNOV 0.00 SEK
2017-04-25 Årsstämma 2017
2017-04-20 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-12-09 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Ordinarie utdelning IMMNOV 0.00 SEK
2016-05-30 Årsstämma 2016
2016-02-24 Bokslutskommuniké 2015
2015-09-28 Extra Bolagsstämma 2015

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Immunovia är ett bioteknikbolag. Bolagets forskning och utveckling är fokuserad mot molekylärdiagnostik, där verksamheten inriktar sig på att driva utveckling och förändring av dagens arbetsmetoder för diagnostisering av komplexa cancerformer och immuna sjukdomar. Visionen är att etablera blodbaserade tester för att tidigt kunna identifiera olika sorters form av pankreascancer. Bolaget grundades 2007 och har sitt huvudkontor i Lund.
2022-06-02 08:30:00

LUND, SWEDEN-Immunovia today announced that Philipp Mathieu has been named Chief Executive Officer and President effective immediately. Since January, Philipp has been acting Chief Executive Officer and President.

Commenting on the announcement, Carl Borrebaeck, Chairman, states: "After carefully evaluating external candidates, the board has decided that Philipp with his extensive financial background and experience is the right person to lead Immunovia through the transition from a research-focused company to a successful commercial enterprise. While serving as acting Chief Executive Officer and President, Philipp demonstrated effective leadership and rapidly advanced the company's strategic priorities. Immunovia is now well positioned for the commercial roll-out of the early detection of pancreatic cancer with its pioneering IMMray™ PanCan-d test in the US."

"I am honored and excited to continue leading our outstanding team through this important phase of Immunovia's evolution. Immunovia is at the forefront of revolutionizing the early detection of pancreatic cancer and addressing a huge unmet medical need which is a tremendously motivating mission," says Philipp Mathieu, CEO and President of Immunovia.

Philipp Mathieu has extensive experience as an adviser on corporate strategy, M&A and capital markets transactions to healthcare and life sciences companies. Most recently, Philipp was a Portfolio Manager and Advisor to a multinational family office. Previously, he was an investment banker focused in the Healthcare sector at Lazard and Lehman Brothers.

For more information, please contact:

Philipp Mathieu

CEO and President

Email: philipp.mathieu@immunovia.com
 

Tobias Bülow

Senior Director Investor Relations and Corporate Communications
Email: tobias.bulow@immunovia.com
Tel: +46 736 36 35 74

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET June 2, 2022.

About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnos­tics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercializa­tion of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare providers, leading experts and patient ad­vocacy groups globally to make this test available to all high-risk pancreatic cancer groups.

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###